ASX:ACW Actinogen Medical (ACW) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About Actinogen Medical Stock (ASX:ACW) Get Actinogen Medical alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume275,000 shsAverage VolumeN/AMarket CapitalizationA$122.18 millionP/E RatioN/ADividend Yield8.76%Price TargetN/AConsensus RatingN/A Company Overview Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia. Read More Receive ACW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Actinogen Medical and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ACW Stock News HeadlinesActinogen achieves agreement with the FDA in a Type C meeting on the manufacturing, clinical and nonclinical activities required for a future US marketing approval of Xanamem ...September 15, 2025 | finance.yahoo.comActinogen Medical Advances Alzheimer’s and Depression TrialsSeptember 7, 2025 | tipranks.com7 market signals flashing red right nowRight now, the same 7 key indicators that predicted 1929, the 1970s stagflation, and the 2008 meltdown are all flashing red at the same time.October 11 at 2:00 AM | American Alternative (Ad)Actinogen trial using intended commercial Xanamem tablet formulation confirms target exposures in fed and fasted statesAugust 27, 2025 | finance.yahoo.comActinogen Medical Releases 2025 Corporate Governance StatementAugust 26, 2025 | theglobeandmail.comActinogen Medical Reinforces Commitment to Corporate GovernanceAugust 25, 2025 | tipranks.comWe're Hopeful That Actinogen Medical (ASX:ACW) Will Use Its Cash WiselyAugust 23, 2025 | finance.yahoo.comActinogen Medical Highlights Alzheimer’s Trial Progress at 2025 Bioshares SummitAugust 22, 2025 | theglobeandmail.comSee More Headlines ACW Stock Analysis - Frequently Asked Questions What other stocks do shareholders of Actinogen Medical own? Based on aggregate information from My MarketBeat watchlists, some other companies that Actinogen Medical investors own include Vocus Group (VOC), Oncolytics Biotech (ONCY), Chorus (CNU), Biosig Technologies (BSGM) and Admedus (AHZ). Industry, Sector and Symbol Stock ExchangeASX SectorMedical Industry Biotechnology Sub-IndustryAutomobiles And Trucks Current SymbolASX:ACW CIKN/A Webwww.actinogen.com.au Phone61 2 8964 7401FaxN/AEmployees1,766Year FoundedN/AProfitability EPS (Trailing Twelve Months)A($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-A$13.04 million Net Margins-131.34% Pretax MarginN/A Return on Equity-82.36% Return on Assets-45.37% Debt Debt-to-Equity Ratio1.62 Current Ratio13.91 Quick Ratio13.73 Sales & Book Value Annual SalesA$9.93 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow2.38 Book ValueA$0.01 per share Price / BookN/AMiscellaneous Outstanding Shares3,080,000,000Free FloatN/AMarket CapA$122.18 million OptionableNot Optionable Beta1.74 Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (ASX:ACW) was last updated on 10/11/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredForget AI, This Will Be the Next Big Tech BreakthroughAfter picking Nvidia in 2016, before it jumped 27,000%... Jeff Brown is back with what he believes will be ...Brownstone Research | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actinogen Medical Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Actinogen Medical With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
